Showing 4441-4450 of 5627 results for "".
- Johnson & Johnson Vision Receives FDA Clearance and CE Mark for Veritas Vision Systemhttps://modernod.com/news/johnson-johnson-vision-receives-fda-clearance-and-ce-mark-for-next-generation-phacoemulsification-machine-veritas-vision-system/2479100/Johnson & Johnson Vision announced the FDA 510(k) clearance and CE mark of its next-generation phacoemulsification device, the Veritas Vision System. The phaco system features technologies that allow surgeons to guide through any lens density with less surge and more stability. The new system
- EyeCare Partners Promotes David Clark to Chief Executive Officerhttps://modernod.com/news/eyecare-partners-promotes-david-clark-to-chief-executive-officer/2479099/EyeCare Partners LLC announced the promotion of David A. Clark to chief executive officer, effective immediately. Mr. Clark joined EyeCare Partners as president in July 2020 after 20 years with MEDNAX Inc., where he was most recently ch
- MIPT and Harvard Researchers Grow Stem Cells to Cure Glaucoma in Micehttps://modernod.com/news/mipt-and-harvard-researchers-grow-stem-cells-to-cure-glaucoma-in-mice/2479095/A joint research carried out by MIPT scientists and Harvard researchers have presented retinal cells that can integrate into the retina. This is the first successful attempt to transplant ganglion cells (retinal neurons that are destroyed by glaucoma) derived from stem cells in a lab setting. Sci
- Next-Generation COVID Vaccines Have Many Different Targetshttps://modernod.com/news/next-generation-covid-vaccines-have-many-different-targets/2479094/Vaccine developers are monitoring the durability of the immune response of current COVID vaccines while racing against variants to provide more options for protection, no matter what happens next in the pandemic, according to a Medscape report
- Study Identifies Mechanism that May Cause Blindnesshttps://modernod.com/news/study-identifies-mechanism-that-may-cause-blindness/2479090/Using laboratory-grown roundworms as well as human and mouse eye tissue, University of Maryland School of Medicine (UMSOM) researchers have identified a new potential mechanism for age-related macular degeneration—the leading cause of blindness among older adults. The UMSOM researchers say
- Gyroscope Therapeutics Files Registration Statement for Proposed Initial Public Offering in the United Stateshttps://modernod.com/news/gyroscope-therapeutics-files-registration-statement-for-proposed-initial-public-offering-in-the-united-states/2479087/Gyroscope Therapeutics announced it has filed a registration statement on Form F-1 with the U.S. Securities and Exchange Commission (SEC) relating to a proposed initial public offering (IPO) in the United States. All American Depositary Shares (ADSS) to be sold in the proposed IPO will be
- Katena Products Acquires Ophthalmic Instrument Maker Asicohttps://modernod.com/news/katena-products-acquires-ophthalmic-instrument-maker-asico/2479080/Katena Products announced it has purchased ophthalmic surgical instrument maker Asico. Terms of the deal were not disclosed Asico’s product range encompasses more 1,500 items, including stainless steel and titanium instruments, single-use cannulas and blades, and diamond knives.
- Qlaris Bio Enrolls First Patient in Phase 1/2 Studies of Investigational Glaucoma Drug QLS-101https://modernod.com/news/qlaris-bio-enrolls-first-patient-in-phase-1-2-studies-of-investigational-glaucoma-drug-qls-101/2479081/Qlaris Bio announced the enrollment of the first patient in the phase 1/2 clinical program for QLS-101, an investigational therapy designed to lower IOP by reducing episcleral venous pressure (EVP) in individuals with glaucoma. QLS-101 is a novel adenosine triphosphate (ATP)-sensitive pota
- Study: Glaucoma May Be More than Just an Issue of Eye Pressurehttps://modernod.com/news/study-glaucoma-may-be-more-than-just-an-issue-of-eye-pressure/2479078/A chemical known to protect nerve cells also slows glaucoma, the leading cause of irreversible blindness, results of a new study in rats show. Led by researchers at NYU Grossman School of Medicine, the study centers on the watery fluid inside the eye on which its function depends. Fluid pr
- Ocumension Therapeutics Licenses Alimera’s Fluocinolone Acetonide Intravitreal Implant in Chinahttps://modernod.com/news/ocumension-therapeutics-licenses-alimeras-fluocinolone-acetonide-intravitreal-implant-in-china/2479075/Alimera Sciences announced that Ocumension Therapeutics has acquired an exclusive license agreement for Alimera’s 0.19mg fluocinolone acetonide intravitreal implant, which Alimera markets elsewhere under the trademark Iluvien. The license grants Ocumension the rights to develop and commercialize